Cynthia A Derdeyn

List of Publications by Citations

64 papers	4,720 citations	32 h-index	66 g-index
66 ext. papers	5,377 ext. citations	9.6 avg, IF	4.59 L-index

#	Paper	IF	Citations
64	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *Journal of Experimental Medicine*, **2009**, 206, 1273-89	16.6	600
63	Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. *Science*, **2004**, 303, 2019-22	33.3	509
62	Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. *Journal of Virology*, **2008**, 82, 3952-70	6.6	487
61	Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. *Journal of Virology*, **2006**, 80, 11776-90	6.6	311
60	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. *Journal of Experimental Medicine*, **2005**, 201, 1407-19	16.6	264
59	Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. *PLoS Pathogens*, **2009**, 5, e1000274	7.6	253
58	Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. *PLoS Pathogens*, **2009**, 5, e1000594	7.6	154
57	Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. *Journal of Virology*, **2006**, 80, 5211-8	6.6	144
56	Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. *Journal of Virology*, **2007**, 81, 1350-9	6.6	117
55	CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. *Immunity*, **2016**, 45, 656-668	32.3	112
54	Depletion of CD4+ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. *Journal of Clinical Investigation*, **2011**, 121, 4433-45	15.9	94
53	Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. *Journal of Virology*, **2009**, 83, 8208-20	6.6	93
52	Role of donor genital tract HIV-1 diversity in the transmission bottleneck. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, E1156-63	11.5	88
51	Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. *Journal of Virology*, **2007**, 81, 5658-68	6.6	82
50	A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. *PLoS Pathogens*, **2010**, 6, e1001064	7.6	81
49	CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells. *PLoS Pathogens*, **2014**, 10, e1004467	7.6	80
48	Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8 cells. *Nature*, **2020**, 578, 154-159	50.4	70

47	Viral and host factors in the pathogenesis of HIV infection. *Current Opinion in Immunology*, **2005**, 17, 366-78	7.8	64
46	Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. *Current Opinion in HIV and AIDS*, **2014**, 9, 210-6	4.2	63
45	Appreciating HIV type 1 diversity: subtype differences in Env. *AIDS Research and Human Retroviruses*, **2009**, 25, 237-48	1.6	62
44	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. *Nature Medicine*, **2020**, 26, 932-940	50.5	60
43	Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5 Restrictive Macaques. *Journal of Virology*, **2017**, 91,	6.6	58
42	Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. *Journal of Virology*, **2007**, 81, 4886-91	6.6	58
41	Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. *Journal of Immunology*, **2014**, 193, 3113-25	5.3	56
40	The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. *Journal of Virology*, **2011**, 85, 905-15	6.6	53
39	Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. *Journal of Virology*, **2010**, 84, 4100-4	6.6	52
38	A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. *PLoS Computational Biology*, **2013**, 9, e1003046	5	45
37	Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. *PLoS Pathogens*, **2013**, 9, e1003173	7.6	42
36	Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. *PLoS Pathogens*, **2015**, 11, e1004565	7.6	39
35	Dualtropic CXCR6/CCR5 Simian Immunodeficiency Virus (SIV) Infection of Sooty Mangabey Primary Lymphocytes: Distinct Coreceptor Use in Natural versus Pathogenic Hosts of SIV. *Journal of Virology*, **2015**, 89, 9252-61	6.6	35
34	Viral characteristics of transmitted HIV. *Current Opinion in HIV and AIDS*, **2008**, 3, 16-21	4.2	34
33	Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques. *PLoS Pathogens*, **2014**, 10, e1003958	7.6	32
32	Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. *Journal of Virology*, **2012**, 86, 12605-15	6.6	32
31	Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies. *Journal of Virology*, **2010**, 84, 6248-53	6.6	32
30	B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. *Journal of Virology*, **2012**, 86, 8031-40	6.6	32

29	Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. *JCI Insight*, **2019**, 4,	9.9	31
28	Cloning and analysis of sooty mangabey alternative coreceptors that support simian immunodeficiency virus SIVsmm entry independently of CCR5. *Journal of Virology*, **2012**, 86, 898-908	6.6	28
27	HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection. *Retrovirology*, **2012**, 9, 76	3.6	27
26	Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 10780-5	11.5	24
25	Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses. *Retrovirology*, **2012**, 9, 22	3.6	23
24	Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. *PLoS Pathogens*, **2016**, 12, e1005989	7.6	23
23	Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope. *Journal of Virology*, **2015**, 89, 8130-51	6.6	20
22	Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. *Virology*, **2010**, 404, 59-70	3.6	18
21	Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein. *PLoS Computational Biology*, **2016**, 12, e1005094	5	17
20	Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques. *Journal of Virology*, **2016**, 90, 1880-7	6.6	14
19	VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120. *Frontiers in Immunology*, **2018**, 9, 3163	8.4	13
18	HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages. *Retrovirology*, **2015**, 12, 25	3.6	13
17	CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo. *Journal of Virology*, **2013**, 87, 9719-32	6.6	12
16	Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants. *Journal of Virology*, **2019**, 93,	6.6	9
15	The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. *PLoS Pathogens*, **2021**, 17, e1009257	7.6	9
14	Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. *Journal of Virology*, **2019**, 93,	6.6	8
13	Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy. *Virology*, **2016**, 487, 75-84	3.6	6
12	Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection. *Virology*, **2014**, 462-463, 295-8	3.6	6

List of Publications

11	Strong T1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. *Science Translational Medicine*, **2019**, 11,	17.5	6
10	New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif. *Journal of Virology*, **2017**, 91,	6.6	5
9	Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART. *PLoS Pathogens*, **2021**, 17, e1009825	7.6	5
8	Infection of ectocervical tissue and universal targeting of T-cells mediated by primary non-macrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes. *Retrovirology*, **2015**, 12, 48	3.6	4
7	Harnessing the protective potential of HIV-1 neutralizing antibodies. *F1000Research*, **2016**, 5,	3.6	4
6	A pathway to HIV-1 neutralization breadth. *Nature Medicine*, **2015**, 21, 1246-7	50.5	2
5	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. *Virology*, **2012**, 433, 410-20	3.6	2
4	Humoral Immune Responses in SIV Infection of Sooty Mangabeys **2014**, 173-195		1
3	Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles.. *Journal of Medicinal Chemistry*, **2022**, 65, 4058-4084	8.3	0
2	Role of HIV Glycans in Transmission and Immune Escape **2014**, 85-115		
1	A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence.. *PLoS Pathogens*, **2022**, 18, e1010488	7.6	